Acne Treatment's Oil-Reducing power put to the test

NCT ID NCT06415279

Completed Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether clascoterone cream 1%, an FDA-approved acne medication, works by reducing sebum (skin oil) production. Researchers will measure forehead oil levels and changes in skin bacteria in 40 participants aged 12 and older with mild to moderate acne. The goal is to confirm the cream's mechanism of action and its effect on the skin microbiome over 12 and 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clascoterone cream 1%
What this could lead to: If successful, this study could confirm that clascoterone cream works by reducing sebum, supporting its use as a targeted acne treatment.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The sebum reduction may not translate to better acne clearance in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACNE VULGARIS

Contacts and locations

Locations

Dermatology Consulting Services, PLLC

High Point, North Carolina, 27262, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.